Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Neurocrine Biosciences Inc trades at $179.72 (market cap $17.82B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NBIX | |
|---|---|---|
Market Cap | $39.89B | $17.82B |
Sector | Health | Health |
52-Week High | $491.22 | $180.55 |
52-Week Low | $278.09 | $123.10 |
Enterprise Value | $38.15B | $16.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Neurocrine Biosciences (NBIX) trades at $177.11, down 1.91% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical signal with moving averages supporting upward trends, while RSI levels indicate potential overbought conditions. Recent news highlights strong sales growth from Ingrezza and pipeline advancements, including the Soleno acquisition, reinforcing long-term growth prospects in neuroscience.
Outlook remains positive with a consensus price target of $194, offering ~9.5% upside. Key opportunities include expanding product portfolio and blockbuster drug performance, while risks involve pipeline execution and market volatility. The stock's high valuation multiples require sustained growth to justify current levels, but analyst sentiment is overwhelmingly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
